¿Pueden los pacientes con artritis reumatoide controlada reducir la dosis de metotrexato de la terapia dirigida y mantener la remisión? Una Revisión Sistemática y Metaanálisis
J Rheumatol. 2023;50(1):36–47 doi: 10.3899/jrheum.220152
This systematic review and meta-analysis of studies evaluated the proportion of patients in remission after the dosage of MTX was tapered, and concludes that patients with controlled RA may taper MTX from targeted therapy with a 10% reduction in the ability to sustain remission for up to 18 months.